Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00504699 · ClinicalTrials.gov registry record · NA

Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients

A NA study, sponsored by New York Medical College.

Terminated
Registry status
NA
Development phase
120
Enrollment target

NCT00504699: Clinical Trial NA study, sponsored by New York Medical College.

NCT00504699 is a NA study that was terminated before completion, run by New York Medical College. The registered enrollment target is 120 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00504699, a NA study, was terminated before completion, sponsored by New York Medical College.

TERMINATED
Registry status
NA
Development phase
120 participants
Enrollment target

Study Summary

Breast cancer patients are commonly treated with drugs that eggs present in the ovary and may reduce their chance for getting pregnant. Their fertility can be preserved by stimulating their ovaries, collecting multiple eggs, fertilize them in the lab and freeze them. Ovarian stimulation increase their estrogen levels in blood.this may stimulate their cancer and increase chance for recurrence. If a medicine that prevent estrogen rise is used (letrozole), this may increase the safety of stimulation. In this study we compared ovarian stimulation in breast cancer patients using letrozole with those who did not undergo stimulation and showed that there is no increase risk for recurrence after a median follow up of 2 years

Interventions

  • PROCEDURE Ovarian stimulation in vitro fertilization cryopreservation

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2002-01
Est. Completion 2018-03-01
Phase NA
New York Medical College

47 total trials

Why NCT00504699 stopped before completion

NCT00504699 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).

The record links to 0 conditions, and to 1 intervention - of which Ovarian stimulation in vitro fertilization cryopreservation is the first listed.

NCT00504699 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00504699 about?

NCT00504699 is a clinical study titled "Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients". Breast cancer patients are commonly treated with drugs that eggs present in the ovary and may reduce their chance for getting pregnant. Their fertility can be preserved by stimulating their ovaries, collecting multiple eggs, fertilize them in the lab and freeze them. Ovarian stimulation increase the...

What is the current status of trial NCT00504699?

This trial is currently terminated. It is a NA study. The enrollment target is 120 participants. The study started on 2002-01. Estimated completion is 2018-03-01.

What interventions are being tested in trial NCT00504699?

The interventions under investigation include: Ovarian stimulation in vitro fertilization cryopreservation (PROCEDURE).

Who is sponsoring clinical trial NCT00504699?

This trial is sponsored by New York Medical College, which has 47 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00504699's enrollment target sits among peer trials

120 762nd of 2000 higher than 1,198 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01174108 · 120 participants · Phase 2

    Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

  • NCT01627301 · 120 participants · NA

    Sympathetic Overactivity in Post-traumatic Stress Disorder

  • NCT02025023 · 120 participants · Phase 3

    Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study

  • NCT02128906 · 120 participants · Phase 2

    Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00504699, the US trial registry maintained by the National Library of Medicine. NCT00504699 (mid enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.